Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248394 | 0.86 | USP30 (0.47) | USP30HDAC4HDAC6DGAT2ANO1 | |
| SCHEMBL14730775 | 0.77 | USP30 (0.49) | USP30HDAC4HDAC6DGAT2ANO1 | |
| SCHEMBL3720765 | 0.70 | USP30 (0.65) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL26554550 | 0.70 | HDAC4 (0.62) | USP30HDAC4HDAC6DGAT2PARP1 | |
| SCHEMBL889094 | 0.70 | HDAC4 (0.62) | USP30HDAC4HDAC6DGAT2PARP1 | |
| SCHEMBL29437052 | 0.70 | HDAC4 (0.62) | USP30HDAC4HDAC6DGAT2PARP1 | |
| SCHEMBL26402532 | 0.70 | NR1H2 (0.58) | USP30HDAC4HDAC6 | |
| SCHEMBL4921150 | 0.70 | USP30 (0.71) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL4924196 | 0.70 | USP30 (0.71) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL994594 | 0.70 | USP30 (0.71) | USP30HDAC4HDAC6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | USP30 1713/4885HDAC4 2738/4885HDAC6 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.